Key statistics
On Friday, Tevogen Bio Holdings Inc (G28:FRA) closed at 0.206, 1.48% above its 52-week low of 0.203, set on Feb 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.207 |
|---|---|
| High | 0.207 |
| Low | 0.206 |
| Bid | 0.223 |
| Offer | 0.249 |
| Previous close | 0.204 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 201.42m |
| Free float | 45.70m |
| P/E (TTM) | -- |
| Market cap | 56.40m USD |
| EPS (TTM) | -0.2138 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 14:25 GMT.
More ▼
Announcements
- Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
- Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue
- Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
- Tevogen CEO Donates Shares to Support Education for Underprivileged Children
- Tevogen CEO Donates Personal Shares to Support Local Fire Department
- Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
- Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
- Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
- Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
- Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
More ▼
